Safety and immunogenicity of a bivalent norovirus vaccine candidate in infants from 6 weeks to 5 months of age: A phase 2, randomized, double-blind trial

Safety and immunogenicity of a bivalent norovirus vaccine candidate in infants from 6 weeks to 5 months of age: A phase 2, randomized, double-blind trial

As infants suffer significant morbidity and mortality due to norovirus-related acute gastroenteritis (AGE), we assessed four formulations of the bivalent virus-like particle (VLP) vaccine candidate (HIL-214) in Panamanian and Colombian infants. 360 infants aged 6 weeks to 5 months were randomly allo...

Full description

Saved in:
Bibliographic Details
Main Authors: Xavier Sáez-Llorens, Rodrigo deAntonio, Eduardo López-Medina, Pío López, Taisei Masuda, Paul M Mendelman, Jim Sherwood, Frank Baehner, Astrid Borkowski
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
Norovirus
vaccine
infants
immunogenicity
reactogenicity
virus-like particles
Online Access:https://www.tandfonline.com/doi/10.1080/21645515.2025.2450878
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items